Readministration of nivolumab for patients with advanced gastric cancer: a case series

NIVO readministration may offer clinical benefit to selected patients with AGC, without inducing severe adverse events.

Authors

Institutions

Publication Details

Journal
ESMO Gastrointestinal Oncology
Published
2026-02-17
DOI
https://doi.org/10.1016/j.esmogo.2026.100307
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Readministration of nivolumab for patients with advanced gastric cancer: a case series

T. Masuishi, M. Ando, K. Muro, K. Honda et al.
ESMO Gastrointestinal Oncology
Cancer Immunotherapy and Biomarkers
article

Readministration of nivolumab for patients with advanced gastric cancer: a case series

T. Masuishi, M. Ando, K. Muro, K. Honda, H. Nishikawa, T. Yamaguchi, M. Tajika, H. Kodama, H. Taniguchi, S. Kadowaki, Y. Narita
article en

Abstract

NIVO readministration may offer clinical benefit to selected patients with AGC, without inducing severe adverse events.

ESMO Gastrointestinal OncologyVol. 11
Aichi Cancer Center (JP), Osaka University of Pharmaceutical Sciences (JP)
Openalex Percentile: Top 51%
Cancer Immunotherapy and Biomarkers
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.